Arbutus Biopharma Corp. v. Modernatx, Inc. addresses the legal standard for inherent anticipation. The case involves the ’127 patent, which claims stable nucleic acid-lipid particles and methods of making and delivering them. The patent seeks to improve the efficiency of introducing nucleic acids into cells.
https://www.jdsupra.com/legalnews/arbutus-biopharma-corporation-fka-2500534/
https://www.jdsupra.com/legalnews/arbutus-biopharma-corporation-fka-2500534/